Study: Drugs to Treat CNS Diseases Take 35% Longer to Develop Than Other Drugs

Pharmpro: Wednesday, March 7, 2012.

Drugs developed to treat central nervous system (CNS) diseases take 35% longer to complete clinical trials and receive regulatory approval compared to other new prescription medicines, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

Between 1996 and 2010, mean clinical-plus-approval phase time for U.S.-approved CNS drugs was 32 months — or 35% longer than that for non-CNS drugs approved during the same period. Read More